Galderma Group
CHF 160.80Change from previous close: −3.04%Absolute change: −CHF 5.05
At a glance
- Revenue growth
- +18.04%
- 2025 vs 2024
- Net income growth
- +165.37%
- 2025 vs 2024
- Net margin
- 11.7%
- 2024: 5.2%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 5,241 | 4,440 | 4,117 | 3,824 | — |
| Cost of revenue | 1,632 | 1,355 | 1,232 | 1,194 | — |
| Gross profit | 3,609 | 3,085 | 2,885 | 2,630 | — |
| Selling, general and administrative | 2,372 | 2,052 | 1,892 | 1,824 | — |
| Research and development | 245 | 260 | 287 | 316 | — |
| Operating income | 876 | 678 | 611 | 406 | — |
| EBIT | 813 | 666 | 575 | 347 | — |
| EBITDA | 1,136 | 959 | 851 | 624 | — |
| Interest expense | 175 | 356 | 564 | 398 | — |
| Pre-tax income | 638 | 310 | 11.0 | -51.9 | — |
| Income tax | 26.0 | 79.0 | 68.0 | 45.0 | — |
| Net income | 613 | 231 | -57.0 | -98.5 | — |
| Net income to common shareholders | 613 | 231 | -57.0 | -98.5 | — |
| Basic EPS | — | 0.97 | -0.24 | -0.41 | -0.65 |
| Diluted EPS | — | 0.97 | -0.24 | -0.41 | -0.65 |
| Average shares (basic) | — | 238 | 238 | 238 | 238 |
| Average shares (diluted) | — | 238 | 238 | 238 | 238 |